Pierre Fabre’s Bladder Cancer Drug, Javlor too Costly for National Health Service, National Institute for Clinical Excellence (NICE) Says

Pharma Times -- t looks like patients with advanced cancer of the urothelial tract will not be getting access to Pierre-Fabre’s Javlor on the National Health Service, after the drug was deemed too expensive by NICE.